Artificial Intelligence in Epidemiology Global Market Report 2024

The artificial intelligence in epidemiology market size has grown exponentially in recent years. It will grow from $0.52 billion in 2023 to $0.67 billion in 2024 at a compound annual growth rate (CAGR) of 29.3%. The growth observed during the historical period can be attributed to the emergence of big data, globalization and increased travel, the demands of public health surveillance, challenges in responding to outbreaks, and the emergence of novel pathogens.

The artificial intelligence in epidemiology market size is expected to see exponential growth in the next few years. It will grow to $1.86 billion in 2028 at a compound annual growth rate (CAGR) of 29.2%. The anticipated growth in the forecast period can be ascribed to challenges in data integration, population growth, increased investments in global health security, the adoption of digital health, the implementation of a one-health approach, and the utilization of digital contact tracing. Key trends expected in the forecast period encompass advancements in computational power, technological innovations in data collection, collaborative efforts with technology companies, the use of real-time data sharing platforms, progress in AI algorithms, advancements in remote sensing technologies, and the application of blockchain for ensuring the security of epidemiological data.

The anticipated increase in the prevalence of chronic diseases is expected to drive the growth of artificial intelligence in the epidemiology market in the future. Chronic diseases are health conditions that persist or have long-lasting effects, typically lasting for three months or more and often worsening over time. AI plays a crucial role in various aspects of chronic disease epidemiology, including risk prediction, modeling disease progression, early detection, and diagnosis. For example, a May 2023 report from The United Nations (UN) stated that chronic diseases account for seven out of 10 deaths in the US, causing over 1.7 million deaths annually. Therefore, the rising burden of chronic diseases is projected to fuel the growth of artificial intelligence in the epidemiology market.

The growing utilization of telemedicine is expected to contribute to the expansion of the artificial intelligence in epidemiology market in the coming years. Telemedicine involves providing medical services remotely through telecommunications technology, enabling the transmission of medical information between patients and healthcare providers using audio, video, or other communication forms. The combination of telemedicine and artificial intelligence in epidemiology offers a powerful synergy, providing a proactive and data-driven approach to addressing public health concerns. It enhances the ability to monitor, evaluate, and respond to health-related data efficiently, particularly during outbreaks or pandemics. For example, an August 2022 report from the Australian Digital Health Agency revealed that between March 2020 and July 2022, 118.2 million telehealth treatment services were provided to 18 million patients, with over 95,000 practitioners actively using telehealth services. Hence, the increasing adoption of telemedicine is propelling the artificial intelligence in epidemiology market.

A notable trend gaining popularity in the artificial intelligence in epidemiology market is the development of specialized AI-based technologies for disease management. Key companies in this market are focusing on creating innovative technologies, such as AI-driven imaging platforms for disease management, to solidify their market position. For instance, in April 2023, Twinn.health, a US-based company specializing in fitness, AI, and machine learning, launched an AI-driven imaging platform for the early detection of age-related diseases. This platform, the first to incorporate magnetic resonance imaging (MRI) data for evaluating frailty risk, serves as a potent tool for early intervention and prevention by detecting age-related disorders earlier than traditional molecular signals and aiding in their management at an early stage.

Major companies in the artificial intelligence in epidemiology market are concentrating on innovative products, including stroke scoring tools, to better cater to the needs of their existing consumers. Stroke scoring tools are clinical assessments used by healthcare professionals to quickly and objectively evaluate the severity of a stroke. For example, in November 2022, Koninklijke Philips N.V., a Netherlands-based medical technology company, introduced the AI-powered CT ASPECT Scoring tool. This tool, applied to non-contrast CT scans, detects early indicators of brain infarction in the treatment of ischemic stroke patients. The program employs AI to automatically identify ASPECTS brain regions and generates an ASPECT score communicated directly to the Picture Archiving and Communication System (PACS). Philips also unveiled its next-generation Advanced Visualization Workspace, including a new cardiac MR Suite with a redesigned workflow and user interface.

In January 2022, Glooko Inc., a US-based digital health company specializing in diabetes management solutions, acquired Xbird for an undisclosed amount. With this acquisition, Glooko aims to reinforce its commitment to machine learning and personalized digital coaching for patients with chronic conditions. Xbird, a Berlin-based company engaged in health AI, focuses on developing JITAI (Just in Time Adaptive Intervention) technologies for proactive healthcare interventions and disease surveillance.

Major companies operating in the artificial intelligence in epidemiology market report are Apple Inc., Alphabet Inc., Microsoft Corporation, Facebook Inc., Roche Holding AG, Pfizer Inc., Johnson & Johnson Services Inc., Amazon Web Services Inc., General Electric Company, Google LLC, Intel Corporation, International Business Machines Corporation, Merck & Co. Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca PLC, Oracle Corporation, GlaxoSmithKline plc, NVIDIA Corporation, Bayer Healthcare, Siemens Healthineers AG, Cognizant Technology Solutions Corporation, Koninklijke Philips N.V., SAS Institute Inc., Epic Systems Corporation, Cerner Corporation, eClinicalWorks LLC, Meditech, Komodo Health, Metabiota Inc.

North America was the largest region in the artificial intelligence in epidemiology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in epidemiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in epidemiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary components of artificial intelligence in epidemiology consist of software and services. Software encompasses a set of programs, instructions, and data that enable a computer or other electronic device to perform specific tasks or operations. Software plays a pivotal role in the implementation of AI in epidemiology, facilitating the analysis of large datasets, modeling the spread of diseases, and making predictions for public health interventions. These software applications are deployed in web-based and cloud-based modes for purposes such as infection prediction and forecasting, disease surveillance, and syndromic surveillance. End-users of such applications include government and state agencies, research laboratories, pharmaceutical and biotechnology companies, as well as healthcare providers.

The artificial intelligence in epidemiology research report is one of a series of new reports that provides artificial intelligence in epidemiology market statistics, including the artificial intelligence in epidemiology industry's global market size, regional shares, competitors with an artificial intelligence in epidemiology market share, detailed artificial intelligence in epidemiology market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in epidemiology industry. This artificial intelligence in epidemiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artificial intelligence in epidemiology market consists of revenues earned by entities by providing disease surveillance and management, predictive modeling, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in epidemiology market also includes sales of real-time monitoring systems and image analysis systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.